Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Mount Sinai Hospital, University Health Network, Toronto, ON M5G 1X5, Canada.
Int J Mol Sci. 2023 Jan 9;24(2):1294. doi: 10.3390/ijms24021294.
Recent advances in treating cutaneous melanoma have resulted in impressive patient survival gains. Refinement of disease staging and accurate patient risk classification have significantly improved our prognostic knowledge and ability to accurately stratify treatment. Undoubtedly, the most important step towards optimizing patient outcomes has been the advent of cancer immunotherapy, in the form of immune checkpoint inhibition (ICI). Immunotherapy has established its cardinal role in the management of both early and late-stage melanoma. Through leveraging outcomes in melanoma, immunotherapy has also extended its benefit to other types of skin cancers. In this review, we endeavor to summarize the current role of immunotherapy in melanoma and non-melanoma skin cancers, highlight the most pertinent immunotherapy-related molecular biomarkers, and lastly, shed light on future research directions.
近年来，治疗皮肤黑色素瘤的方法取得了显著进展，患者的生存率得到了显著提高。疾病分期的细化和患者风险的准确分类显著提高了我们的预后知识和准确分层治疗的能力。毫无疑问，优化患者治疗效果最重要的一步是癌症免疫疗法的出现，其形式为免疫检查点抑制（ICI）。免疫疗法在早期和晚期黑色素瘤的治疗中确立了其主要地位。通过利用黑色素瘤的结果，免疫疗法也将其获益扩展到其他类型的皮肤癌。在这篇综述中，我们努力总结免疫疗法在黑色素瘤和非黑色素瘤皮肤癌中的作用，强调最相关的免疫疗法相关分子生物标志物，并最后展望未来的研究方向。
Zotero 插件